Opposition procedure before the European Patent Office

Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’s

Retrieved on: 
Wednesday, August 23, 2023

MELBOURNE, Australia and SAN FRANCISCO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the European Patent Office has granted Alterity a new composition of matter patent.

Key Points: 
  • MELBOURNE, Australia and SAN FRANCISCO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the European Patent Office has granted Alterity a new composition of matter patent.
  • The patent secures broad protection over a new class of iron chaperone drug candidates for treating major neurodegenerative diseases.
  • “Through restoration of normal iron balance in the brain, we have the potential to slow disease progression of diseases including Parkinson’s and Alzheimer’s.
  • The composition of matter patent covers more than 150 novel pharmaceutical compositions that are designed to redistribute the excess iron implicated in neurodegenerative diseases.

BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results

Retrieved on: 
Wednesday, August 9, 2023

SUNNYVALE, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the second quarter of 2023 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2023 with the Securities and Exchange Commission.

Key Points: 
  • SUNNYVALE, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the second quarter of 2023 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2023 with the Securities and Exchange Commission.
  • The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights.
  • On July 12, 2023, the planned Data Safety Monitoring Board (DSMB) meeting was held utilizing the adaptive statistical analysis plan reviewed by FDA in the second quarter.
  • Second Quarter 2023 Financial Results:
    Revenues were approximately $43,000 for the three months ended June 2023, compared to approximately $974,000 in the three months ended June 2022, due primarily to the timing of collaboration agreement revenues.

Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Party

Retrieved on: 
Monday, July 17, 2023

Oppositions were pursued by GSK and an anonymous opponent represented by a third party against EP3258951B1 .

Key Points: 
  • Oppositions were pursued by GSK and an anonymous opponent represented by a third party against EP3258951B1 .
  • In an oral proceedings hearing on July 11 2023, the opposition division of the European Patent Office ruled in favor of maintaining the broad claims in the patent as granted to Compugen.
  • "We are delighted with the decision of the opposition division of the European Patent Office ruling in favor of maintenance of the broad claims in the patent as granted, supporting our patent strategy in novel target discovery."
  • Compugen was represented by Markus Rieck, LL.M., Partner, Patent Attorney, Fuchs Patentanwälte Partnerschaft mbB and Thomas Wolter, Partner, Patent Attorney, Mewburn Ellis LLP.

AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)

Retrieved on: 
Monday, June 26, 2023

This new European patent provides intellectual property protection for masitinib in the treatment of mCRPC until 2042.

Key Points: 
  • This new European patent provides intellectual property protection for masitinib in the treatment of mCRPC until 2042.
  • Masitinib is positioned in combination with docetaxel as a treatment of mCRPC patients who are eligible to chemotherapy; that is to say, it is administered directly following the metastatic hormone-sensitive prostate cancer (mHSPC) treatment space.
  • The Notice of Allowance (NOA) means that the European Patent Office intends to grant the patent application, EP4175639A1, after the completion of certain formal procedural steps.
  • A European NOA is issued after an examiner determines that a patent application satisfies all requirements for patentability under the European Patent Convention.

OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe

Retrieved on: 
Monday, June 26, 2023

The opposition division of European Patent Office ruled to maintain the patent as granted with minor modifications.

Key Points: 
  • The opposition division of European Patent Office ruled to maintain the patent as granted with minor modifications.
  • ROCKVILLE, Md., June 26, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, and OpGen subsidiary, Ares Genetics, which strives to become a leader in bacterial genomics and AI-powered prediction of antimicrobial resistance (AMR), announced today that one of its key patents under opposition has been successfully maintained.
  • In September 2021, an opposition was filed by a Swedish opponent against the patent grant by the European Patent Office.
  • In a hearing on Thursday, June 22, 2023, the opposition division of the European Patent Office ruled in favor of maintaining the patent as granted with a minor amendment to one of the claims.

In Victory for Motif, U.S. Patent Office to Review Impossible Foods Patent

Retrieved on: 
Tuesday, June 20, 2023

BOSTON, June 20, 2023 /PRNewswire/ -- In a highly-anticipated ruling by its Patent Trial and Appeal Board (PTAB), the U.S. Patent and Trademark Office announced Friday it would institute inter partes review (IPR) of Patent 9,943,096 B2 claimed by Impossible Foods.

Key Points: 
  • BOSTON, June 20, 2023 /PRNewswire/ -- In a highly-anticipated ruling by its Patent Trial and Appeal Board (PTAB), the U.S. Patent and Trademark Office announced Friday it would institute inter partes review (IPR) of Patent 9,943,096 B2 claimed by Impossible Foods.
  • The ruling commences an administrative trial, expected to take about a year, on the validity of one of Impossible Foods' most important patents.
  • Motif FoodWorks petitioned for review of the patent after Impossible sued Motif in federal court last year, alleging patent infringement in using heme to create plant-based meat substitutes.
  • Late last year, the European Patent Office revoked an EU patent held by Impossible.

Soligenix Announces European Patent Grant for Use of Dusquetide in Oral Mucositis

Retrieved on: 
Tuesday, May 16, 2023

PRINCETON, N.J., May 16, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European Patent Office has granted a patent entitled "Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis".  This granted patent builds on similar intellectual property issued in the United States (U.S.), New Zealand, Japan, Australia and Singapore, as well as many pending patent applications in other jurisdictions worldwide. The granted claims will cover therapeutic uses of dusquetide (active ingredient in SGX942) and related innate defense regulator (IDR) analogs, and adds to composition of matter claims for dusquetide and related analogs that have been issued in the U.S. and worldwide.

Key Points: 
  • This granted patent builds on similar intellectual property issued in the United States (U.S.), New Zealand, Japan, Australia and Singapore, as well as many pending patent applications in other jurisdictions worldwide.
  • "Soligenix continues to pursue broad patent coverage for its dusquetide technology, first with composition of matter claims followed by therapeutic use claims in oral mucositis ," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix.
  • "Having successfully pursued composition of matter claims in jurisdictions worldwide, we continue to pursue therapeutic use claims like those issued in the U.S. previously and in Europe with this most recent patent.
  • The therapeutic use claims are expected to be generally valid until 2034, which provides significant patent protection and life to dusquetide and our other IDR analogs."

Windtree Therapeutics Announces Issuance of New Dual Mechanism SERCA2a Activator Patent

Retrieved on: 
Monday, April 17, 2023

3599243, providing patent coverage for the dual mechanism SERCA2a Activator class of drug candidates.

Key Points: 
  • 3599243, providing patent coverage for the dual mechanism SERCA2a Activator class of drug candidates.
  • The new patent, titled: “17BETA-HETEROCYCLYL-DIGITALIS LIKE COMPOUNDS FOR THE TREATMENT OF HEART FAILURE,” provides patent protection until July 2038 for the family of compounds with a dual mechanism of action.
  • Windtree believes therapies that activate SERCA2a represent a potential important advancement in heart failure treatment for patients,” said Craig Fraser, CEO and President of Windtree Therapeutics.
  • Compounds that activate SERCA2a have been aggressively pursued as much sought-after targets in the treatment of heart failure, and Windtree has found a unique mechanism that activates SERCA2a.”

Vistagen Receives New European Patent for AV-101

Retrieved on: 
Thursday, April 6, 2023

Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that the European Patent Office (EPO) has granted the Company a patent for AV-101, its oral NMDAR (N-methyl-D-aspartate receptor) glycine site antagonist.

Key Points: 
  • Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that the European Patent Office (EPO) has granted the Company a patent for AV-101, its oral NMDAR (N-methyl-D-aspartate receptor) glycine site antagonist.
  • The patent relates to the synthesis of AV-101 and certain chemical intermediaries, which synthesis yields AV-101 in commercial quantities and has the scalability for commercial manufacture.
  • The new European patent is a counterpart to previously granted U.S. patent 11,427,530 and will be in effect until at least 2039.
  • “Expanding our patent portfolio for all of our product candidates is an ongoing priority to support our global development and commercialization strategies across our pipeline,” said Shawn Singh, Chief Executive Officer of Vistagen.

Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana’s ‘190 Patent is Not Valid

Retrieved on: 
Friday, March 24, 2023

MUNICH, Germany, March 24, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that, following a hearing on March 24, 2023, the Technical Board of Appeal (the “TBA”) of the European Patent Office (the “EPO”) issued an oral judgement that NuCana’s European Patent 2955190 (the “’190 patent”) is not valid.

Key Points: 
  • MUNICH, Germany, March 24, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that, following a hearing on March 24, 2023, the Technical Board of Appeal (the “TBA”) of the European Patent Office (the “EPO”) issued an oral judgement that NuCana’s European Patent 2955190 (the “’190 patent”) is not valid.
  • The TBA reversed the previous decisions of the EPO’s Examination Division which issued NuCana’s ‘190 patent and of the EPO’s Opposition Division which upheld this patent in 2021.
  • In July 2022, the Regional Court of Dusseldorf issued a judgement that fully endorsed the decision of the EPO’s Opposition Division.
  • NuCana is well-capitalized, all of our clinical programs remain on track and we expect multiple data announcements in 2023.”